CN1544475A - 一种古糖酯及其制备方法和应用 - Google Patents
一种古糖酯及其制备方法和应用 Download PDFInfo
- Publication number
- CN1544475A CN1544475A CNA2003101057189A CN200310105718A CN1544475A CN 1544475 A CN1544475 A CN 1544475A CN A2003101057189 A CNA2003101057189 A CN A2003101057189A CN 200310105718 A CN200310105718 A CN 200310105718A CN 1544475 A CN1544475 A CN 1544475A
- Authority
- CN
- China
- Prior art keywords
- acid
- ancient
- ancient sugar
- polyguluronic
- sugar ester
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000002148 esters Chemical class 0.000 title claims abstract description 50
- 239000002253 acid Substances 0.000 title claims abstract description 12
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 15
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000003814 drug Substances 0.000 claims abstract description 12
- 238000011282 treatment Methods 0.000 claims abstract description 12
- 230000015556 catabolic process Effects 0.000 claims abstract description 5
- 238000006731 degradation reaction Methods 0.000 claims abstract description 5
- 238000001035 drying Methods 0.000 claims abstract description 5
- 238000001914 filtration Methods 0.000 claims abstract description 4
- 238000000108 ultra-filtration Methods 0.000 claims abstract description 4
- 239000000126 substance Substances 0.000 claims abstract description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 12
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 8
- AKEJUJNQAAGONA-UHFFFAOYSA-N sulfur trioxide Chemical compound O=S(=O)=O AKEJUJNQAAGONA-UHFFFAOYSA-N 0.000 claims description 8
- XTHPWXDJESJLNJ-UHFFFAOYSA-N sulfurochloridic acid Chemical group OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 claims description 8
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 6
- -1 alkali metal salt Chemical class 0.000 claims description 6
- 238000001556 precipitation Methods 0.000 claims description 6
- AEMOLEFTQBMNLQ-BZINKQHNSA-N D-Guluronic Acid Chemical compound OC1O[C@H](C(O)=O)[C@H](O)[C@@H](O)[C@H]1O AEMOLEFTQBMNLQ-BZINKQHNSA-N 0.000 claims description 5
- 239000003153 chemical reaction reagent Substances 0.000 claims description 5
- 235000006408 oxalic acid Nutrition 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 4
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 claims description 4
- 230000018044 dehydration Effects 0.000 claims description 3
- 238000006297 dehydration reaction Methods 0.000 claims description 3
- 238000010298 pulverizing process Methods 0.000 claims description 3
- PWEBUXCTKOWPCW-UHFFFAOYSA-N squaric acid Chemical compound OC1=C(O)C(=O)C1=O PWEBUXCTKOWPCW-UHFFFAOYSA-N 0.000 claims description 3
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 2
- 229910052783 alkali metal Inorganic materials 0.000 claims description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 claims description 2
- 229910017604 nitric acid Inorganic materials 0.000 claims description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 2
- 235000015320 potassium carbonate Nutrition 0.000 claims description 2
- 235000011118 potassium hydroxide Nutrition 0.000 claims description 2
- 238000000746 purification Methods 0.000 claims description 2
- 235000017550 sodium carbonate Nutrition 0.000 claims description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 2
- 239000011593 sulfur Substances 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- 238000005406 washing Methods 0.000 claims description 2
- 239000003513 alkali Substances 0.000 claims 1
- 230000008021 deposition Effects 0.000 abstract description 4
- 229920000615 alginic acid Polymers 0.000 abstract description 2
- 235000010443 alginic acid Nutrition 0.000 abstract description 2
- 229960001126 alginic acid Drugs 0.000 abstract 1
- 239000000783 alginic acid Substances 0.000 abstract 1
- 150000004781 alginic acids Chemical class 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000009991 scouring Methods 0.000 abstract 1
- 230000001180 sulfating effect Effects 0.000 abstract 1
- 230000019635 sulfation Effects 0.000 abstract 1
- 238000005670 sulfation reaction Methods 0.000 abstract 1
- 208000008281 urolithiasis Diseases 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 23
- 210000003734 kidney Anatomy 0.000 description 17
- 210000002784 stomach Anatomy 0.000 description 15
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 7
- 230000037396 body weight Effects 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 210000002700 urine Anatomy 0.000 description 5
- 229910052725 zinc Inorganic materials 0.000 description 5
- 239000011701 zinc Substances 0.000 description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 238000000465 moulding Methods 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 230000000069 prophylactic effect Effects 0.000 description 4
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 230000003118 histopathologic effect Effects 0.000 description 3
- 206010025482 malaise Diseases 0.000 description 3
- 231100000915 pathological change Toxicity 0.000 description 3
- 230000036285 pathological change Effects 0.000 description 3
- 238000004062 sedimentation Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- 229920002683 Glycosaminoglycan Polymers 0.000 description 2
- 208000000913 Kidney Calculi Diseases 0.000 description 2
- 206010029148 Nephrolithiasis Diseases 0.000 description 2
- 208000031320 Teratogenesis Diseases 0.000 description 2
- 208000006568 Urinary Bladder Calculi Diseases 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000002489 hematologic effect Effects 0.000 description 2
- 230000002262 irrigation Effects 0.000 description 2
- 238000003973 irrigation Methods 0.000 description 2
- 238000002504 lithotomy Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- RQALKBLYTUKBFV-UHFFFAOYSA-N 1,4-dioxa-7-thiaspiro[4.4]nonane Chemical compound O1CCOC11CSCC1 RQALKBLYTUKBFV-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000632227 Antenoron Species 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 206010006987 Calculus bladder Diseases 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 208000015924 Lithiasis Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 208000035992 Postmortem Changes Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- AEMOLEFTQBMNLQ-UHFFFAOYSA-N beta-D-galactopyranuronic acid Natural products OC1OC(C(O)=O)C(O)C(O)C1O AEMOLEFTQBMNLQ-UHFFFAOYSA-N 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 201000000210 bladder calculus Diseases 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008614 cellular interaction Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 230000001779 embryotoxic effect Effects 0.000 description 1
- 231100000238 embryotoxicity Toxicity 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 244000144992 flock Species 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000000387 litholytic effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000000643 oven drying Methods 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229920000447 polyanionic polymer Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 231100001028 renal lesion Toxicity 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005201 scrubbing Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200310105718 CN1213071C (zh) | 2003-11-25 | 2003-11-25 | 一种古糖酯及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200310105718 CN1213071C (zh) | 2003-11-25 | 2003-11-25 | 一种古糖酯及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1544475A true CN1544475A (zh) | 2004-11-10 |
CN1213071C CN1213071C (zh) | 2005-08-03 |
Family
ID=34333875
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200310105718 Expired - Fee Related CN1213071C (zh) | 2003-11-25 | 2003-11-25 | 一种古糖酯及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1213071C (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015000411A1 (zh) * | 2013-07-02 | 2015-01-08 | 中国科学院上海药物研究所 | 一种硫酸酯化聚古洛糖酸多糖或其可药用盐及其制备方法和用途 |
CN105343121A (zh) * | 2015-09-28 | 2016-02-24 | 青岛海洋生物医药研究院股份有限公司 | 聚古罗糖醛酸硫酸酯在制备抗乙型肝炎病毒的药物中的应用 |
CN107880150A (zh) * | 2017-12-05 | 2018-04-06 | 四川大学 | 一种提高海藻酸盐中古洛糖醛酸单元含量的方法 |
CN110204625A (zh) * | 2019-06-06 | 2019-09-06 | 青岛海洋生物医药研究院股份有限公司 | 一种可释放一氧化氮的聚古罗糖醛酸硝酸酯及其制备方法和应用 |
CN110403197A (zh) * | 2019-07-31 | 2019-11-05 | 浙江海洋大学 | 一种褐藻胶口服液的应用 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7220670B2 (ja) | 2016-12-30 | 2023-02-10 | グリーン、バレー、(シャンハイ)、ファーマスーティカルズ、カンパニー、リミテッド | オゾンを用いた多糖類の分解方法 |
-
2003
- 2003-11-25 CN CN 200310105718 patent/CN1213071C/zh not_active Expired - Fee Related
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10058566B2 (en) | 2013-07-02 | 2018-08-28 | Shanghai Institute Of Materia Medica Chinese Academy Of Sciences | Sulfated polygulonic acid polysaccharide or pharmaceutical salt thereof, preparation method therefor and use thereof |
CN105358582B (zh) * | 2013-07-02 | 2018-09-21 | 中国科学院上海药物研究所 | 一种硫酸酯化聚古洛糖酸多糖或其可药用盐及其制备方法和用途 |
CN105358582A (zh) * | 2013-07-02 | 2016-02-24 | 中国科学院上海药物研究所 | 一种硫酸酯化聚古洛糖酸多糖或其可药用盐及其制备方法和用途 |
KR20160029817A (ko) * | 2013-07-02 | 2016-03-15 | 상하이 인스티튜트 오브 마테리아 메디카 차이니즈 아카데미 오브 싸이언시즈 | 황산화 폴리굴론산 폴리사카라이드 또는 그의 제약 염, 그의 제조 방법 및 그의 용도 |
JP2016523301A (ja) * | 2013-07-02 | 2016-08-08 | シャンハイ インスティテュート オブ マテリア メディカ チャイニーズ アカデミー オブ サイエンシーズ | 硫酸化ポリグロン酸多糖又はその薬学的塩、その調製方法及びその使用 |
EA028655B1 (ru) * | 2013-07-02 | 2017-12-29 | Шангхай Инститьют Оф Матириа Медика Чайниз Акэдеми Оф Сайнсиз | Сульфатированный полисахарид полигулоновой кислоты или фармацевтическая соль, способ получения и применение |
KR102258569B1 (ko) * | 2013-07-02 | 2021-05-28 | 상하이 인스티튜트 오브 마테리아 메디카 차이니즈 아카데미 오브 싸이언시즈 | 황산화 폴리굴론산 폴리사카라이드 또는 그의 제약 염, 그의 제조 방법 및 그의 용도 |
JP2019090056A (ja) * | 2013-07-02 | 2019-06-13 | シャンハイ インスティテュート オブ マテリア メディカ チャイニーズ アカデミー オブ サイエンシーズ | 硫酸化ポリグロン酸多糖又はその薬学的塩、その調製方法及びその使用 |
AU2014286711B2 (en) * | 2013-07-02 | 2018-05-10 | Shanghai Institute Of Materia Medica Chinese Academy Of Sciences | Sulfated polygulonic acid polysaccharide or pharmaceutical salt thereof, preparation method therefor and use thereof |
WO2015000411A1 (zh) * | 2013-07-02 | 2015-01-08 | 中国科学院上海药物研究所 | 一种硫酸酯化聚古洛糖酸多糖或其可药用盐及其制备方法和用途 |
CN105343121B (zh) * | 2015-09-28 | 2018-07-06 | 青岛海洋生物医药研究院股份有限公司 | 聚古罗糖醛酸硫酸酯在制备抗乙型肝炎病毒的药物中的应用 |
CN105343121A (zh) * | 2015-09-28 | 2016-02-24 | 青岛海洋生物医药研究院股份有限公司 | 聚古罗糖醛酸硫酸酯在制备抗乙型肝炎病毒的药物中的应用 |
CN107880150A (zh) * | 2017-12-05 | 2018-04-06 | 四川大学 | 一种提高海藻酸盐中古洛糖醛酸单元含量的方法 |
CN110204625A (zh) * | 2019-06-06 | 2019-09-06 | 青岛海洋生物医药研究院股份有限公司 | 一种可释放一氧化氮的聚古罗糖醛酸硝酸酯及其制备方法和应用 |
CN110403197A (zh) * | 2019-07-31 | 2019-11-05 | 浙江海洋大学 | 一种褐藻胶口服液的应用 |
Also Published As
Publication number | Publication date |
---|---|
CN1213071C (zh) | 2005-08-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101040867A (zh) | 岩藻聚糖硫酸酯在制备防治神经退行性疾病药物或保健品中的应用 | |
CN1181016A (zh) | 使用透明质酸治疗间质性膀胱炎 | |
CN1021629C (zh) | 无悬浮剂的稳定的碱式蔗糖硫酸铝悬液药物组合物 | |
CN101028282A (zh) | 低分子量褐藻多糖硫酸酯在制备治疗肾脏疾病的药物中的用途 | |
CN110787192B (zh) | 一种海带中可溶性膳食纤维在制备降糖的药物和功能性食品中的应用 | |
CN101036667A (zh) | 一种外科手术防粘连凝胶及其制备方法 | |
CN1544475A (zh) | 一种古糖酯及其制备方法和应用 | |
CN109453188B (zh) | 一种沙虫多糖在制备防治骨质疏松药物中的应用 | |
CN1775274A (zh) | 一种止咳化痰的药物组合物及其制备方法 | |
CN1686441A (zh) | 一种用于调节免疫力的中药胶囊、制备方法及其用途 | |
CN1884260A (zh) | 一种化合物、其合成方法及其在制备驱除重金属和清除自由基药物中的应用 | |
CN1202067C (zh) | 药用级枸橼酸铁的制备方法 | |
US20230250199A1 (en) | Low molecular weight chondroitin sulfate, composition, preparation method and use thereof | |
CN101028252A (zh) | 一种注射用乙酰半胱氨酸粉针药物组合物及其制备方法 | |
CN1479744A (zh) | 晶状葡糖胺金属硫酸盐及其制备方法 | |
CN1671744A (zh) | 低分子量过硫酸化多糖 | |
CN1259344C (zh) | O-取代羧甲基壳聚糖在外科手术防粘连材料的应用 | |
CN1016313B (zh) | 治疗白内障的药物配方 | |
CN104523804B (zh) | 一种增加骨密度的胶囊及其制备方法 | |
CN1207308C (zh) | 树舌多糖,其制备方法和以该化合物为活性成分的药物组合物 | |
CN106580938A (zh) | 一种氨丁三醇有机酸盐及其制备方法和应用 | |
CN1189177C (zh) | 甲壳低聚糖硫酸酯和/或壳聚糖硫酸酯作为制备降血糖药物中的应用 | |
CN1137681C (zh) | 积雪甙防粘膜及制备方法 | |
CN1271580A (zh) | 治疗和预防铅中毒的药物及其制法 | |
CN114846147A (zh) | 低分子量硫酸软骨素、包含其的组合物、其制备方法以及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20151030 Address after: 266071 Hongkong East Road, Laoshan District, Shandong, China, No. 23, No. Patentee after: Qingdao Ocean University of China Holdings Ltd. Address before: 266003 No. 5 fish Hill Road, Shandong, Qingdao Patentee before: Ocean University of China |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20160525 Address after: 266071 Hongkong East Road, Laoshan District, Shandong, China, No. 23, No. Patentee after: MARINE BIOMEDICAL RESEARCH INSTITUTE OF QINGDAO Co.,Ltd. Address before: 266071 Hongkong East Road, Laoshan District, Shandong, China, No. 23, No. Patentee before: Qingdao Ocean University of China Holdings Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20050803 |
|
CF01 | Termination of patent right due to non-payment of annual fee |